Cargando…

Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy

The digestion of gluten generates toxic peptides, among which a highly immunogenic proline-rich 33-mer from wheat α-gliadin, that trigger coeliac disease. Neprosin from the pitcher plant is a reported prolyl endopeptidase. Here, we produce recombinant neprosin and its mutants, and find that full-len...

Descripción completa

Detalles Bibliográficos
Autores principales: del Amo-Maestro, Laura, Mendes, Soraia R., Rodríguez-Banqueri, Arturo, Garzon-Flores, Laura, Girbal, Marina, Rodríguez-Lagunas, María José, Guevara, Tibisay, Franch, Àngels, Pérez-Cano, Francisco J., Eckhard, Ulrich, Gomis-Rüth, F. Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343461/
https://www.ncbi.nlm.nih.gov/pubmed/35915115
http://dx.doi.org/10.1038/s41467-022-32215-1
_version_ 1784761012210106368
author del Amo-Maestro, Laura
Mendes, Soraia R.
Rodríguez-Banqueri, Arturo
Garzon-Flores, Laura
Girbal, Marina
Rodríguez-Lagunas, María José
Guevara, Tibisay
Franch, Àngels
Pérez-Cano, Francisco J.
Eckhard, Ulrich
Gomis-Rüth, F. Xavier
author_facet del Amo-Maestro, Laura
Mendes, Soraia R.
Rodríguez-Banqueri, Arturo
Garzon-Flores, Laura
Girbal, Marina
Rodríguez-Lagunas, María José
Guevara, Tibisay
Franch, Àngels
Pérez-Cano, Francisco J.
Eckhard, Ulrich
Gomis-Rüth, F. Xavier
author_sort del Amo-Maestro, Laura
collection PubMed
description The digestion of gluten generates toxic peptides, among which a highly immunogenic proline-rich 33-mer from wheat α-gliadin, that trigger coeliac disease. Neprosin from the pitcher plant is a reported prolyl endopeptidase. Here, we produce recombinant neprosin and its mutants, and find that full-length neprosin is a zymogen, which is self-activated at gastric pH by the release of an all-β pro-domain via a pH-switch mechanism featuring a lysine plug. The catalytic domain is an atypical 7+8-stranded β-sandwich with an extended active-site cleft containing an unprecedented pair of catalytic glutamates. Neprosin efficiently degrades both gliadin and the 33-mer in vitro under gastric conditions and is reversibly inactivated at pH > 5. Moreover, co-administration of gliadin and the neprosin zymogen at the ratio 500:1 reduces the abundance of the 33-mer in the small intestine of mice by up to 90%. Neprosin therefore founds a family of eukaryotic glutamate endopeptidases that fulfils requisites for a therapeutic glutenase.
format Online
Article
Text
id pubmed-9343461
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-93434612022-08-03 Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy del Amo-Maestro, Laura Mendes, Soraia R. Rodríguez-Banqueri, Arturo Garzon-Flores, Laura Girbal, Marina Rodríguez-Lagunas, María José Guevara, Tibisay Franch, Àngels Pérez-Cano, Francisco J. Eckhard, Ulrich Gomis-Rüth, F. Xavier Nat Commun Article The digestion of gluten generates toxic peptides, among which a highly immunogenic proline-rich 33-mer from wheat α-gliadin, that trigger coeliac disease. Neprosin from the pitcher plant is a reported prolyl endopeptidase. Here, we produce recombinant neprosin and its mutants, and find that full-length neprosin is a zymogen, which is self-activated at gastric pH by the release of an all-β pro-domain via a pH-switch mechanism featuring a lysine plug. The catalytic domain is an atypical 7+8-stranded β-sandwich with an extended active-site cleft containing an unprecedented pair of catalytic glutamates. Neprosin efficiently degrades both gliadin and the 33-mer in vitro under gastric conditions and is reversibly inactivated at pH > 5. Moreover, co-administration of gliadin and the neprosin zymogen at the ratio 500:1 reduces the abundance of the 33-mer in the small intestine of mice by up to 90%. Neprosin therefore founds a family of eukaryotic glutamate endopeptidases that fulfils requisites for a therapeutic glutenase. Nature Publishing Group UK 2022-08-01 /pmc/articles/PMC9343461/ /pubmed/35915115 http://dx.doi.org/10.1038/s41467-022-32215-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
del Amo-Maestro, Laura
Mendes, Soraia R.
Rodríguez-Banqueri, Arturo
Garzon-Flores, Laura
Girbal, Marina
Rodríguez-Lagunas, María José
Guevara, Tibisay
Franch, Àngels
Pérez-Cano, Francisco J.
Eckhard, Ulrich
Gomis-Rüth, F. Xavier
Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
title Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
title_full Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
title_fullStr Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
title_full_unstemmed Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
title_short Molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
title_sort molecular and in vivo studies of a glutamate-class prolyl-endopeptidase for coeliac disease therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343461/
https://www.ncbi.nlm.nih.gov/pubmed/35915115
http://dx.doi.org/10.1038/s41467-022-32215-1
work_keys_str_mv AT delamomaestrolaura molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT mendessoraiar molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT rodriguezbanqueriarturo molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT garzonfloreslaura molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT girbalmarina molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT rodriguezlagunasmariajose molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT guevaratibisay molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT franchangels molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT perezcanofranciscoj molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT eckhardulrich molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy
AT gomisruthfxavier molecularandinvivostudiesofaglutamateclassprolylendopeptidaseforcoeliacdiseasetherapy